UK drug giant GSK is to shed 200 jobs at its manufacturing plant in Barnard Castle, County Durham to cut costs ahead of generic competition for products made at the facility, which include the anti-emetic Zofran (ondansentron).
As more and more delivery firms set their sights on the specialty pharma sector, existing specialty players are increasingly abandoning established licensing strategies in favour of developing drugs in-house to compete.
inVentive Health has been contracted to provide marketing and branding services for fellow US based generic injectables developer GeneraMedix, specifically focusing on the latter’s epoprostenol hypertension treatment.
The challenges in establishing a regulatory pathway for biogenerics were discussed at a recent FTC roundtable, with a FDA official saying in most cases it will be “impossible” to establish that the APIs are identical.
Competition commissioner Neelie Kroes said that some drugmakers operating in the EU are deliberately stalling the introduction of generics, costing European patients around €3bn ($3.87bn) a year more to buy medicines.
The possible sell-off of Enzon Pharmaceuticals’ biotechnology drugs business has come under fire by one of the firm’s shareholders, DellaCamera Capital Management, which says it is opposed to the move.
King Pharmaceuticals’ $1.6bn (€1.2bn) acquisition of Alpharma heads a busy week of deals that has seen J&J agree to pay $438m for Omrix and India’s Sun further its presence in the US narcotic APIs sector through the purchase of Chattem Chemicals.
Pfizer’s Exubera failure need not be the final nail in the coffin for inhaled biopharmaceuticals as long as developers focus on proving “healthcare value” and addressing payer needs, according to Bruckner Group’s David Balekdjian.